Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIFU plus chemotherapy in inoperable pancreatic cancer
DRKS00012367Phase 2Recruiting
- Sponsor
- Universitätsklinikum Bonn
- Start
- Jul 2017
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of gemcitabine, nab-paclitaxel, erlotinib, oxaliplatin, fluorouracil and 1 more in pancreatic cancer (PC) (2 arms), sponsored by Universitätsklinikum Bonn. Primary endpoints: Feasibility of HIFU plus chemotherapy, Safety of HIFU plus chemotherapy and 1 more. Started Jul 2017; status: recruiting.
02
Drugs
gemcitabinenab-paclitaxelerlotiniboxaliplatinfluorouracil
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on DRKS00012367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00012367.